OncoMatch/Clinical Trials/NCT04100174
Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy
Is NCT04100174 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for prostate cancer.
To determine if fBT+sRT is superior to standard care in terms of urinary toxicity by having fewer patients experience a minimal important decline (MID) in urinary irritation/obstructive QoL
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04100174 currently recruiting?
Yes, this trial is currently recruiting patients.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages